Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Tetsuya Fukumoto is a pioneering urologic surgeon whose research focuses on advancing robot-assisted surgery for high-risk prostate and kidney cancers. His most influential work, "Role of robot‐assisted radical prostatectomy in locally advanced prostate cancer" (59 citations), challenges conventional treatment paradigms by demonstrating the viability of robotic surgery as a primary or multimodal therapy for very high-risk disease, where prognosis is typically poor. Dr. Fukumoto has further refined surgical techniques through studies like his 2021 work showing that a low RENAL Nephrometry Score can eliminate the need for ureteral catheter insertion during robot-assisted partial nephrectomy (15 citations), reducing patient morbidity. His investigations into extended lymph node dissection for intermediate-to high-risk prostate cancer (2025, 4 citations) critically evaluate whether this aggressive approach improves biochemical recurrence rates, while his research on extended robot-assisted prostatectomy as monotherapy for very-high-risk patients (2021, 4 citations) explores avoiding neoadjuvant or adjuvant therapies. Notably, Dr. Fukumoto is at the forefront of surgical innovation, having evaluated Japan’s new HINOTORI™ robotic platform against the da Vinci® system in sacrocolpopexy (2025, 2 citations), contributing to the global expansion of robotic surgery technology. His work directly impacts clinical decision-making for complex urologic cancers.